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RESEARCH ARTICLE
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Evaluation of T lymphocyte frequency provides prognostic information for patients with oral
squamous cell cancer (OSCC). However, the effect of simultaneously evaluating T cell frequency
and assessing suppressive elements and defects in antigen-processing machinery (APM) has not
been clarified. Simultaneous characterization of CD3+, CD8+, FoxP3+, CD163+, and PD-L1+ cells using
multispectral imaging was performed on sections from 119 patients with HPV– OSCC. Expression of
β2-microglobulin, MHC class I heavy chain, and large multifunctional peptidase 10 was quantified,
and all data were correlated with patient outcome. We found that, consistent with previous reports,
high numbers of CD8+ T cells at the invasive margin correlated significantly with prolonged overall
survival (OS), while the number of FoxP3+ or PD-L1+ cells did not. Compiling the number of FoxP3+
or PD-L1+ cells within 30 μm of CD8+ T cells identified a significant association with a high number
of suppressive elements close to CD8+ T cells and reduced OS. Integrating this information into a
cumulative suppression index (CSI) increased correlation with OS. Incorporating tumor expression
levels of APM components with CSI further improved prognostic power. This multiparametric
immune profiling may be useful for stratifying patients with OSCC for clinical trials.
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Oral squamous cell cancer (OSCC) represents a leading cause of cancer worldwide, with substantial
mortality and morbidity. In contrast to other head and neck squamous cell cancer (HNSCC) subtypes,
most OSCCs are attributed to smoking and alcohol, and an association with HPV infection is rare
(1–4). While treatment with anti-PD-1 was recently shown to improve outcome for some patients with
OSCC, a majority of patients progress and die of their disease (5, 6).
Since the risk stratification based on tumor size, lymph node, and distant metastasis (TNM staging), combined with histological grading alone, is not sufficient to predict the prognosis of OSCC
patients (7, 8), additional prognostic biomarkers are urgently required. For colorectal cancer (CRC),
the infiltration of adaptive immune cells composed of T lymphocytes (CD3) with cytotoxic (CD8) and
memory (CD45RO) phenotype located at the invasive margin (IM) and tumor center, and assessed
using digital imaging and objective assessment tools, represents a significant independent parameter
to predict recurrence and survival (9–11). Similar trends have been reported for other cancer types;
however, due to unique characteristics, each histology needs to be evaluated separately (12–14). In
contrast, a strong CD3+/CD8+ T cell infiltrate and a high frequency of CD4+CD69+ T cells correlated
with increased overall survival (OS) of HNSCC patients (15–17). However, the prognostic effect of
the frequency of CD4+CD25+FoxP3+ Tregs remains controversial (18–20). In this context it is noteworthy that most studies analyzing immune surveillance of HNSCC focused either on HPV+ cancers
or did not determine the patients’ HPV status (21). As HPV+ HNSCCs are frequently associated with
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Figure 1. Differences in density and location
of immune infiltrate in OSCC, as a typical example of squamous cell carcinoma,
compared with colorectal cancer, as a typical
example of intestinal adenocarcinoma. (A)
Representative example with demonstration of
topographic position of CD8+ infiltrate in OSCC
(original magnification, ×40). (B) Representative example of CD8+ infiltrate in colorectal
cancer (CRC) (original magnification, ×40). (C)
Enumeration of immune cell infiltrate using the
Definiens platform. In OSCC, most CD8+ cells are
located within the stromal side invasive margin
(IM), while, in CRC, the majority of CD8+ cells
are located within the tumor and tumor side
IM. Data are represented as dot plots (mean ±
SEM). Two-tailed unpaired t test was performed
to test statistical significance. n = 55 for OSCC,
n = 199 for CRC. CT, core of tumor.

increased T and B cell infiltrates, higher levels of IFN-γ secretion, and increased numbers of FoxP3+ T
cells, all features of antiviral responses that may translate into enhanced antitumor immune responses
(22–26), distinguishing HPV+ and HPV– tumors is essential (17, 27).
Immune surveillance is mediated by the composition of the tumor microenvironment (TME); it is
affected by a multitude of strategies tumors use to escape immune recognition. These include (a) the lack
or downregulation of tumor antigen expression, (b) loss or reduced expression of MHC class I molecules
due to impaired expression of components of the antigen-processing machinery (APM), and (c) increased
expression of immune-suppressive molecules, like the programmed death-like receptor ligand 1 (PD-L1)
and the nonclassical HLA-G and HLA-E antigens (28–31).
So far to our knowledge, a comprehensive analysis of HPV– OSCC, characterizing the composition and location of immune cells within and in close proximity to tumor cells in parallel with an
assessment of tumor immune escape mechanisms and association with clinical parameters, has not
been performed. In order to get better insights into these processes and their effect on patient survival,
which might help in selecting patients with rather adverse prognosis for specific immunotherapies, this
study analyzed different components of immune surveillance/escape using multispectral imaging and
objective assessment combined with conventional IHC (32, 33).

Results
Density of CD8+ T cells at the IM predicts outcome of HPV– OSCC patients. Analysis of HPV– OSCC identified
that the IM harbored a more dense immune cell infiltrate than the tumor centers, a difference that was more
pronounced than in the published data on CRC (9) (Figure 1). Based on these results, our studies focused
on evaluating cells at the IM, which was further divided into tumor and stromal sides of the IM (Figure 2).
A correlation between a high density of CD3+CD8+ T cells at the IM and improved OS was found (Figure 3, A and B). Through enumeration of CD8+ T cells of the IM, we found that the CD8+ T cell number
on the tumor side had a greater effect on OS than that on the stromal side (P = 0.01, Figure 3, A and B),
suggesting that, even within the IM, the relative location of CD8+ T cells (tumor or stroma) plays a role.
Distance from FoxP3+ Tregs to CD8+ T cells predicts outcome in HPV– OSCC. While an increased number of
CD3+ FoxP3+ T cells on the stromal side of IM was associated with increased OS, the difference was not
insight.jci.org   https://doi.org/10.1172/jci.insight.93652
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Figure 2. Representative image of immune cell infiltrate in an OSCC tumor. Tissue sections were simultaneously stained for 7 antigens. Images
(original magnification, ×20) with a high density of immune cell infiltrate were taken from stromal and tumor side invasive margin. Red overlay,
recognized by software as tumor; green overlay, recognized by the software as stroma.

significant (Figure 3, C and D). Similar findings have been reported for CRC, HPV+ OSCC, and gastric cancer
(34, 35). Based on a positive correlation between an increased number of Tregs and the CD8+ T cell infiltrate
(Figure 4), we posited that Tregs recruited to the TME might not be close enough to the CD8+ T cells to suppress their effector function. To investigate this hypothesis, the local density of FoxP3+ T cells around each
CD8+ T cell was determined for the tumor and stromal side of the IM and normalized for CD8+ T cells. Preliminary analysis of 34 tumor cases revealed that an increased number of Tregs within 30 μm of CD8+ cells
(FoxP330μmCD8n) was associated with worse outcome (Figures 5 and 6). Extrapolating this formula to the
entire cohort of 119 patients identified a highly significant correlation, with significantly worse OS for patients
with higher numbers of FoxP3+ T cells within 30 μm of CD8+ T cells; this was true on the stromal and tumor
side of the IM (Figure 7, A and B). We next evaluated whether the FoxP3/CD8 ratio would provide a similar prognostic power to that seen above. For both the tumor and stromal sides of the IM, the FoxP3/CD8
ratio, while trending in the same direction as the FoxP330μmCD8n evaluation, failed to provide a prognostic
signature that was statistically significant (Figure 7, C and D). These data suggest that Tregs more proximal to
CD8+ T cells are more effective at suppressing anticancer function.
Distance from PD-L1+ cells to CD8+ T cells and PD-L1/CD8 ratio predict outcome in HPV– OSCC. Since enumeration of PD-L1+ cells had no correlation with outcome (Figure 3, E and F), we evaluated the effect of
insight.jci.org   https://doi.org/10.1172/jci.insight.93652
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Figure 3. Effect of immune infiltrate density at the invasive margin on overall survival. Higher densities of CD8+, but not FoxP3+, T cells and PD-L1+
tumor cells at the invasive margin (IM) predict favorable OS, while this effect is more profound on the stromal side of the IM. Densities of CD8, FoxP3, and
PD-L1 on both the tumor and stromal sides of the IM were enumerated using PerkinElmer inForm software. A median cutoff was used to separate high
and low infiltrate. Log-rank statistics were performed to determine significance. n = 119.

having more PD-L1+ cells within 30 μm of CD8+ T cells (PD-L130μmCD8n). Patients with a high number
of PD-L1+ cells within 30 μm of CD8+ T cells, normalized to CD8 T cell numbers, had a significantly
worse outcome (Figure 8, A and B), with the effect being greatest for cells on the stromal side of the IM
(P < 0.0005). We also found that the ratio of PD-L1/CD8+ cells for both the stromal and tumor side of
the IM provided a strong biomarker for OS (Figure 8, C and D).
Combining assessment of suppressive elements further separates patient populations. Since suppression mediated by FoxP3+ and PD-L1+ cells would be expected to be additive, we created a suppression index (SI) based
on the variables enumerated above: specifically, the number of FoxP3+ cells and the number of PD-L1+
cells within 30 μm of a CD8+ T cell, normalized to CD8+ T cell numbers. Patients who were in the top 50%
for both categories were in the high SI category and had the worst OS. Patients who were in the top 50%
insight.jci.org   https://doi.org/10.1172/jci.insight.93652
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Figure 4. Independent analysis and correlation of CD8+/FoxP3+ immune cell infiltrates at the tumor and stromal side of the invasive margins. (A) Tumor side and
(B) stromal side. Data are represented in a scattered plot with the best fit (solid line)
and 95% confidence interval (dotted line) shown. Statistical test for P values was
linear regression. n = 124 for both tumor and stroma.

for one category were intermediate. Those in the lower 50% for both FoxP3
and PD-L1 had the lowest SI and the highest OS. Evaluating the SI for both
the tumor and stromal side of the IM provided a highly significant prognostic
biomarker for OS (Figure 9).
The SI is a strong prognostic marker, independent of tumor size and UICC stage.
To compare the well-known International Union Against Cancer (UICC)
tumor-staging prognostic system with the SI, the OSCC cohort was separated
into two groups based on OS (Figure 10). Patients with UICC stage III disease
were grouped with those with UICC stage I and II disease based on their coinciding approximately 70% 5-year OS. The SI was highly predictive for OS independent of OSCC UICC stage (I–III), particularly on the stromal side of the IM, as
patients with the lowest SI here achieved almost 90% 5-year OS compared with
less than 40% for patients with the highest SI (Figure 11, A and B). The median
cut point for the FoxP330um CD8n cells for the tumor and stromal side (Figure 11, C and D) did not provide a significant separation in OS, but the stromal
side tended to show a better separation of the curves. The same analysis of the
PD-L130umCD8n cells was not significant for the tumor side, but evaluation of
the stromal side provided a significant (P = 0.007) prognostic biomarker for OS
(Figure 11, E and F) In patients with stage IV disease, the SI had the potential to
discriminate patients with different disease course, in particular by evaluating the
tumor side of the IM rather than the stromal site (Figure 12, A and B). Here the
median cut point for the FoxP330um CD8n cells for the tumor side, but not the
stromal side, provided a significant (P = 0.003) separation in OS (Figure 12, C
and D). In the case of PD-L130umCD8n cells the median cut point for both the tumor and stromal sides of
the tumor provided a significant (P = 0.019 and P = 0.05, respectively) prognostic marker of OS, but the tumor
side, as seen for FoxP3, tended to give better separation of the curves (Figure 12, E and F).
APM defects associated with worse outcome. As defects in antigen presentation represent immune escape strategies of tumors that can define disease outcome, these were assessed using MHC class I β2-microglobulin
(β2m) and heavy chain (HC) as well as the large multifunctional peptidase 10 (LMP10). Using chromogenic
IHC, patients with high (international rating score [IRS] 4–12) versus low (IRS 0–3) cytoplasmic expression
levels of β2m showed a tendency toward a worse OS (relative risk [RR] of death 1.64, P = 0.08), independent
of T- and N-stage as well as grading, though this effect did not reach statistical significance (Figure 13A). This
effect was predominantly accounted for in patients with UICC stage I–II tumors (RR 2.77, P = 0.07, Figure
13B), rather than in those with UICC stage III–IV tumors (RR 1.23, P = 0.54). In contrast, a high membranous β2m expression level was not a predictive biomarker in this study. Staining results for cytoplasmic expression of HC10 mAb were in concordance with cytoplasmic β2m data showing a strong yet insignificant trend
toward worse OS (RR 1.6, P = 0.08) in patients with high versus low cytoplasmic class I HC expression levels.
No difference could be seen as dividing UICC stage I–II versus UICC stage III–IV tumors or membranous
β2m expression levels. Regarding LMP10, patients with high versus low cytoplasmic expression showed a
slight yet insignificant trend toward worse OS (RR 1.44, P = 0.28). No differences were detected when dividing patients based on their UICC stage or in nuclear LMP10 level expression. Cumulative results regarding
the cytoplasmic expression of the three APM components are shown in Figure 14A.
Cumulative SI provides greater prognostic power for HPV– OSCC. By combining the SI generated from the stromal
and tumor side of the IM, a cumulative suppressive index (CSI) was generated (Figure 14B). This CSI scoring
system combines the evaluation of FoxP3+ and PD-L1+ within 30 μm of CD8+ T cells at both the stromal and
tumor side of the IM. Each time a patient was in the top 50% for their cohort, they received 1 point. If they were
in the top 50% for all 4 assessments, they could receive a total of 4 points (Figure 14B). Applying the CSI to all
patients (Figure 14C), or to stage I–III (Figure 14D) or stage IV patients (Figure 14E), identified patients with a
insight.jci.org   https://doi.org/10.1172/jci.insight.93652
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Figure 5. Presentation of a relationship analysis. A reference cell (star)
was picked and surrounding cell types were enumerated within a certain
distance. The overall relationship parameter is a function of an average of
all certain cell types within the entire field (original magnification, ×20).

significant probability to do worse had the highest CSI. Even with patients with stage IV disease, patients with
a CSI score of 0 had a 60% 5-year survival compared with those with a score of 4, who rapidly succumbed to
their disease (Figure 14E). Thus, even for patients with late-stage HPV– OSCC, the CSI is still meaningful for
separation of OSCC patients with rather good clinical outcome from those with poor clinical outcome.
Evaluating the effect of MHC class I β2m and HC as well as LMP10 expression levels, we also identified that the effect of defects in these pathways could be additive, with patients with defects in all 3
pathways having the worst outcome (Figure 14A). Since these defects were independent of the FoxP3- and
PD-L1–mediated suppression, we combined both the CSI and the APM defects. In doing so, we created
an 8-point scoring system, ranging from 0 to 7 (Figure 14F). Each point, or category, is based on a median
insight.jci.org   https://doi.org/10.1172/jci.insight.93652
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Figure 6. Optimization of the cutoff of the distance of FoxP3+ cells within specified distance of CD8+ T cells, normalized for CD8+ T cell number. Cumulative survival for a test cohort of 34 patients characterized as being above (high) or below (low) the median for FoxP320μmCD8n (A),
FoxP330μmCD8n (B), FoxP345μmCD8n (C), and total FoxP3 (D). The number of FoxP3+ T cells within 30 μm of a CD8+ T cell, normalized to number of
CD8+ T cells (FoxP330μmCD8n) (B), provides the best statistical cutoff point and was therefore used for the analysis of the entire cohort of patients.
Numbers of FoxP3+ T cells and distance were determined using PerkinElmer inForm and R script and were normalized to the number of CD8+ T cells
(FoxP330μmCD8n). A median cutoff was used to separate high and low infiltrate. Kaplan-Meier survival plots were made, and statistics were generated using log-rank test. n = 34.

cutoff. A score of 7 would imply that all categories (PD-L1 and FoxP3 suppression in tumor and stroma
as well as APM defects that include the cytoplasmic portions of β2m, HC10, and LMP10) were above the
median cutoff. In contrast, patients with a score of 0 would be in the lowest group for all inhibitory mechanisms specified. This CSI plus cytoplasmic APM index provided a striking and highly significant separation
of patients; for patients given a score of 0, 100% survived 5 years, and for those given a score of 7, all the
patients had died within 30 months of follow-up time.

Discussion
This immune profiling study objectively assessed not only the frequency and composition of the immune
cell infiltrate, but also the cell-to-cell topography and thereby the probability of cell-to-cell interactions,
with additional correlation to clinical and prognostic parameters. Multispectral imaging performed on
HPV– OSCC enabled us to objectively assess 6 markers and quantify the number of cells expressing that
marker and their cartographic coordinates on one 4-μm section of FFPE tissue (33).
Based on the density, composition, and localization of immune cell infiltrates, in particular of CD8+ T
cells, the immunoscore was developed, which had independent prognostic relevance in CRC, in addition to
other cancer types (36–38). In regards to HNSCC, various immune subsets have been correlated with clinical outcome (39, 40), but the majority of these reports either focused exclusively on HPV+ HNSCC or did
not distinguish patient populations based on the HPV status. However, high-throughput analyses revealed
that HPV+ and HPV– HNSCCs are two distinct clinical entities, which have specific molecular features and
an altered immune phenotype characterized by CD8+ T cell infiltration (40).
insight.jci.org   https://doi.org/10.1172/jci.insight.93652
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Figure 7. Effect of topographic distance of FoxP3+ T
cells from CD8+ T cells on prognosis. A high number of
FoxP3+ cells within 30 μm of CD8+ T cells, normalized to
CD8+ T cell numbers (FoxP330μmCD8n), on the tumor (A)
and the stromal (B) side of the invasive margin present
a significant prognostic marker for worse OS, while the
ratio of FoxP3/CD8 T cells failed to provide a significant
prognostic signature (C and D). Absolute numbers of T
cells as well as distance relationship were determined
using PerkinElmer inForm and R script and were normalized to the number of CD8+ T cells. A median cutoff was
used to separate high and low distance relationships.
Kaplan-Meier survival plots were made, and statistics
were generated using log-rank test. n = 119.

To date, our study, consisting of 119 patients from two centers, represents one of the largest HPV–
OSCC studies. Consistent with other reports, our results indicated a favorable association between high
CD8+ T cell density and OSCC patient survival (41). By focusing exclusively on CD8+ T cells on the tumor
side of the IM, long-term survivors were identified independent from tumor stage, suggesting a prognostic
value of the immune cell repertoire in the TME. In contrast to our data, an inverse correlation between
tumor PD-L1 expression and outcome of HNSCC patients has recently been shown in a Chinese cohort
(42), which might be at least partially explained by the lack of distinction of the HPV status and/or a distinct pathogenesis among ethnic groups. This might be of great impact, as high PD-L1 expression levels
can be mediated by external stimuli, including cytokines secreted from immune cells, or intrinsic constitutive expression due to gene amplification (43), utilization of an ectopic promoter by translocation (44),
disruption of the 3′ untranslated region of PD-L1 (45), or aberrant signaling pathways (46).
Based on our previous data in melanoma (32), we investigated the ratios as well as the spatial relationship between CD8+ T cells and immune suppressors. Adapted from an optimal separation of a test
cohort of 34 patients (Figure 6), FoxP3 and PD-L1 expression was analyzed within a 3-lymphocyte-wide
distance (30 μm) around CD8 T cells; the numbers of FoxP3+ and PD-L1+ cells were normalized to the
total number of CD8 T cells, and this number was equal to the SI. By normalizing the number of FoxP3
and PD-L1 cells to CD8+ T cells in the region of interest, this SI takes into consideration both the active
suppressive mechanisms, FoxP3+ and PD-L1+ cells as well as an overall “suppressed” or absent anticancer immune response, characterized by a low number of CD8 T cells. Using this approach, OSCC
patients with a low SI survived much longer compared with those with a high SI, while the OS for those
with an intermediate SI fell right in the middle. Upon separating the patients by tumor stage, the stromal
SI was more important in stage I–III patient, while the tumor SI appeared to be more important in stage
IV patients. These results lead to the hypothesis that, in earlier tumor stages, without apparent organ
metastases, the most important function of stromal immune infiltrate involves the control of tumor
spreading, while in late-stage tumors with apparent organ metastases, tumor-infiltrating immune cells
represent a favorable signature. Next, we combined the SI of the stromal and the tumor side of the IM to
create the CSI and found that patients with the highest CSI had reduced survival. To further strengthen
insight.jci.org   https://doi.org/10.1172/jci.insight.93652
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Figure 8. Effect of topographic distance of PD-L1+ T cells from CD8+ T cells on prognosis. A high number of PD-L1+ within 30 μm of CD8+ T cells
(PD-L130μmCD8n) (A and B) as well as the ratio of PD-L1/CD8 T cells (C and D) on the tumor and the stromal side of the invasive margin present a significant
prognostic marker for worse OS. Absolute numbers of T cells as well as distance relationship were determined using PerkinElmer inForm and R script and
were normalized to the number of CD8+ T cells. A median cutoff was used to separate high and low distance relationships. Kaplan-Meier survival plots
were made, and statistics were generated using log-rank test. n = 119.

our scoring system, the expression of APM components was determined. The cytoplasmic expression
of APM components inversely correlated with OS of OSCC patients (Figure 14A). Thus, higher cytoplasmic expression of HC and β2m might indicate a defect in the export of MHC class I molecules to the
cell surface, a mechanism already described in virus-infected cells, leading to reduced T cell–mediated
killing (47). So far, altered MHC class I APM component expression in HNSCC and other cancers has
been documented by others but has not been correlated to the immune cell infiltrate of the tumor specimen (48–50). The underlying molecular mechanisms of the disturbed APM component expression have
not been analyzed in detail, but deregulation, rather than structural abnormalities, appears to be main
cause (51). By combining APM parameters with CSI, patients with a 100% 5-year survival could be
identified and distinguished from those who rapidly progressed, with none surviving at 30 months. Our
study, while small in size and in need of validation, not only confirms the importance of CD8+ T cells
in prognosis, but also highlights the complexity of the TME, suggesting that the assessment of multiple
parameters is necessary in order to better identify those patients in need of more aggressive treatment
strategies. Future research should include a validation cohort and should evaluate whether to weigh
suppressive elements or APM by some other factor than the median score and evaluate whether that may
further improve outcome prediction of the presented index. For that matter, the predictive value of other
APM components (e.g., TAP1/2, calreticulin/calnexin, ERp57, ERAP1/2) should also be tested. Additionally, our process of normalizing the FoxP3 and PD-L1 relationships within 30 μm of a CD8 T cell to
the number of CD8 T cells includes a reduced number of CD8 T cells as a component of the suppressive
index. This reduced CD8 T cell number may represent the result of active suppression, but, in many
patients with “cold” tumors, it may be indicative of the absence of an immune response and not actual
insight.jci.org   https://doi.org/10.1172/jci.insight.93652
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Figure 9. Effect of a suppression index on prognosis. Use of a suppression index (SI)
incorporating both the number of FoxP3+ cells and the number of PD-L1+ cells within 30
μm of a CD8+ T cell, normalized to CD8+ T cell number, on both the tumor (A) and the
stromal (B) side of the invasive margin separates patients into 3 distinct prognostic
groups, providing a highly significant biomarker. Here, the expressions based on median
cutoff of FoxP330μmCD8n and PD-L130μmCD8n were added together and ranked from high
(score of 2) to low (score of 0). Patients who were in the top 50% for both categories were
in the high SI category and had the worst OS. Patients who were in the top 50% for one
category were intermediate, and those in the lower 50% for both FoxP330μmCD8n and
PD-L130μmCD8n had the lowest SI and the highest OS. Log-rank statistics were performed
to determine significance. The top P value refers to all comparisons, the bottom P value
refers to the difference between the lowest and highest score. n = 119.

suppression. This could have important ramifications for clinical trial design by identifying patients who
need an adoptive immunotherapy or a cancer vaccine as a component of their combination immunotherapy. Furthermore, the separation we identified supports evaluation of the CSI in additional histologies.
A limitation of these studies is the substantial user input for staining and evaluation of multispectral
images; for example, these include manual staining protocols and the selection of regions of interest,
spectral libraries, and exposure times in inForm, which are prone to interobserver variability. In our
opinion, what is needed now is to move multiplex immunohistochemical staining to an automated CLIA
platform, make improvements to image acquisition technology to optimize signal strength for each slide,

Figure 10. Stage distribution and basic patient characteristics. Kaplan-Meier survival plot of the
cohort based on UICC stage.
insight.jci.org   https://doi.org/10.1172/jci.insight.93652
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Figure 11. Effect of the suppression index and distance relationships on OS in stage I–III OSCC patients. (A and B) Using a suppression index (SI) incorporating both FoxP330μmCD8n and PD-L130μmCD8n presents a significant prognostic marker for OS on the stromal side (B) but not on the tumor side of the
invasive margin (IM) (A). (C–F) In stage I–III OSCC patients, only a high number of PD-L130μmCD8n cells on the stromal side of the IM (F) presents a significant biomarker, marking an unfavorable OS. For A and B, ranks were assigned as presented in Figure 9. For C–F, a median cutoff was used to separate high
and low distance relationships. Kaplan-Meier survival plots were made, and statistics were generated using log-rank test. n = 59.

modify software so that it can automatically identify regions of interest, and accelerate the time required
to complete the analyses. Moving forward, we are working with collaborators to test improved image
analysis algorithms and are evaluating automated multiplex staining methods. Successful development
and application of these tools should lead to accelerated analysis times and validated panels that could
be used in “real-time” clinical decision making.
Overall, these data, while preliminary and in need of validation, are consistent with a large body
of work and signify the importance of T cell responses in HPV– OSCC. They provide a rationale for
the utilization of multiplex imaging in characterizing the possible escape mechanisms operational in a
given patient. It is our vision that this type of assessment, which may include additional markers and
possibly other methodologies (52), will ultimately allow for the precise tailoring of combination immunotherapy agents and aid in identifying patients that may require treatment intensification.
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Figure 12. Effect of the suppression index and distance relationships on OS in stage IV OSCC patients. (A and B) Using a suppression index (SI) incorporating both the FoxP330μmCD8n and the PD-L130μmCD8n provides a significant prognostic marker for OS on both the tumor (A) and the stromal side of the
invasive margin (IM) (B), with a more profound effect on the tumor side (A). (C–F) A high number of FoxP330μmCD8n (C) and PD-L130μmCD8n (E) cells on the
tumor side of the IM provides a significant biomarker, identifying an unfavorable OS. For A and B, ranks were assigned as presented in Figure 9. For C–F,
a median cutoff was used to separate high and low distance relationships. Kaplan-Meier survival plots were made, and statistics were generated using
log-rank test. n = 60.

Methods
Study population and selection criteria. The study included 152 OSCC primary tumors from Halle, Germany, and 12 OSCC primary tumors from Portland, Oregon, USA. Forty-five patients were dropped
from the study due to HPV positivity or lack of IM in the tumor slides, resulting in 119 patients being
available for study. UICC stage distribution as well as basic patient characteristics are summarized in
Figure 10 and Tables 1 and 2.
Bright-field IHC and analysis. For bright-field IHC, the mAbs NAMB (β2m; SP09-36), HC10 (HLA class
I HC; HSP09-35), and TO-7 (LMP10; SP08-225) were used (30). Tissue samples were deparaffinized
with xylol and transferred via alcohol into aqua dest (Elix 5 Filter System, Merck-Millipore). Antigen
decloaking was performed by steaming the slides with a preheated T-EDTA buffer (ZUC029-500, 1:10
dilution, Zytomed Systems) at pH 9.0 and 98°C for 20 minutes in an oven (Braun, type 3216). After coolinsight.jci.org   https://doi.org/10.1172/jci.insight.93652
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Figure 13. Effect of cytoplasmic expression of β2m on OS. (A) Kaplan-Meier curve highlighting the strong yet insignificant tendency toward a prognostic effect of high levels of
cytoplasmic expressed β2m (IRS 4–12 vs. 0–3), leading to a 1.64-fold increase (P = 0.08) in the
relative risk (RR) of death, independent of T- and N-stage and grading. (B) This effect was
predominantly accounted for by patients with T1–2 stage tumors (RR 2.77, P = 0.07), rather
than in T3–4 stage tumors (RR 1.23, P = 0.54, data not shown).

ing down for 20 minutes and rinsing with aqua dest, slides were blocked for 7–10
minutes with 3% H2O2. Following another rinsing step and application of washing buffer (ZUC202-2500, 1:20 solution, Zytochem Plus HRP Kit/Plus Polymer
System, Zytomed), the antibodies β2m (1:50 dilution), HC10 (1:2,500 dilution),
and LMP10 (1:200 dilution) were added dropwise on the tissue area and incubated for 30 minutes at room temperature. Antibody removal was performed by vacuum followed by a washing step. Then, slides were incubated with a biotinylated
secondary antibody (Broad Spectrum, Zytochem Plus HRP Kit, Zytomed) for
15 minutes at room temperature and rinsed with washing buffer, followed by 15
minutes of incubation with HRP (Zytochem Plus HRP, Zytomed). The epitopes
were visualized with DAB (10 minutes, DAB Substrate Kit, Zytomed). After further rinsing steps (aqua dest), the slides were counterstained with hemalaun (Dr.
K. Hollborn & Sons) for 30 seconds, transferred into xylol, and covered (Eukitt,
ORSAtec) for bright-field analysis.
Staining results were semiquantitatively evaluated utilizing the IRS, as described
by Remmele et al. (53). In short, staining intensity (0, negative; 1, low; 2, moderate;
3, strong positive) and the percentage of stained cells (0, negative; 1, <10%; 2, 10%–
50%; 3, 51%–80%; 4, >80%) were evaluated, and the IRS score was then calculated
as the product of the two, ranging from 0–12. Tissue samples were independently categorized by two pathologists (CW and DB). Ten percent of all cases plus all cases presenting any technical challenges were coreviewed by both pathologists to harmonize
and ensure reproducibility of the APM scoring. All the remaining cases were scored by one pathologist (DB).
Multiplex IHC and analysis. Multispectral imaging was performed as previously described in detail
in the supplemental section of Feng et al. (32) with minor changes, using mAbs directed against
PD-L1 (E1L3N, Cell Signaling), CD8 (M239, Spring Bioscience), FoxP3 (236A/E7, Abcam), CD3
(2GV6, Ventana, prediluted, incubation for 45 minutes), CD163 (MRQ26, Ventana), and cytokeratin
(AE1/AE3, DAKO, 1:100 dilution, incubation for 45 minutes) as well as DAPI (Invitrogen). TSACy5 (PerkinElmer Inc.), TSA-Cy3 (PerkinElmer Inc.), TSA-FITC (PerkinElmer Inc.), TSA-Alexa594
(Life Technologies), TSA-Biotin-Alexa514 (PerkinElmer Inc., Life Technologies), and TSA-Coumarin
(PerkinElmer Inc.) were applied to each antibody. Slides were imaged using the PerkinElmer Vectra
platform. A “hotspot” analysis was performed. Three ×20 fields from the IM were manually selected based on the highest lymphocytic infiltrate. Tumor (cytokeratin+) and stromal (cytokeratin–) areas
within hotspots were identified using inForm software (example in Figure 2), and cell number and
cartographic coordinates (distance from each cell and location within tumor or stroma) for each cell
were obtained (example Figure 5). Images were analyzed in small batches using PerkinElmer inForm
and R script for cell phenotype enumeration and relationship analysis. Cells that were positive for both
CD3 and CD8 were classified as CD8+. Cells that were CD3+ and had nuclear staining for FoxP3 were
considered FoxP3+. Except for CD3+PD-L1+ double-positive cells, any cell that expressed PD-L1 was
considered a PD-L1+ cell. This includes both tumor cells and macrophages. Evaluation of FoxP3+ and
PD-L1+ within 30 μm of a CD8 T cell, normalized to the number of CD8 T cells, was performed by
first obtaining the number of FoxP3+ or PD-L1+ cells within 30 μm of a CD8 T cell and then normalizing that to the number of CD8 T cells according to the following formula: number of FoxP3 within 30
μm of a CD8 T cell/total CD8s = FoxP330μmCD8n. The median number of FoxP330μmCD8n was 1.93 ×
10–3 for the tumor and 1.28 × 10–3 A for the stromal side of the invasive margin. A similar formula was
applied for characterizing PD-L1: number of PD-L1+ macrophages and tumor cells within 30 μm of
a CD8 T cell/total CD8s = PD-L130μmCD8n. The median number of PD-L130μmCD8n was 1.32 × 10–3
for the tumor and 1.25 × 10–3 A for the stromal side of the invasive margin.
insight.jci.org   https://doi.org/10.1172/jci.insight.93652
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Figure 14. The cumulative suppression index is a highly indicative prognostic marker superior to the prognostic index of the single markers. (A)
Kaplan-Meier curve showing the influence of the combined cytoplasmatic expression levels of β2m, HC, and LMP10 on OS. Patients were separated
as above or below the median for each marker. A score of 0 represents below-median cutoff expression, and a score of 3 represents high expression
for all three APM components. (B) Combining suppression indices (SI) from tumor and stroma to obtain cumulative suppression index (CSI). Each
column represents FoxP330μmCD8n and PD-L130μmCD8n in tumor and stroma, with red indicating above-median cutoff, marking increased suppression. (C) Analysis of the entire cohort demonstrates the highly significant stepwise reduction of OS based on an increasing CSI, with 0 representing
the lowest and 4 representing the most suppression relative to CD8+ T cells. (D) Kaplan-Meier curve for the CSI for patients with stage I–III disease.
(E) Kaplan-Meier curve for the CSI for patients with stage IV disease. (F) Analysis of CSI in combination with the 3 APM components, demonstrating a highly significant stepwise reduction of OS based on an increasing score. A score of 0 represents low suppression and low cytoplasmatic APM
expression (below-median cutoff); a score of 7 represents high (above-median) cutoff for all 7 categories. (A and C–F) Log-rank statistics were
performed to determine significance. The top P value refers to all comparisons, the bottom P value refers to the difference between the lowest and
highest score. n = 119 (A, C, and F); 59 (D); E = 60 (E).

Statistics. Statistical analyses for bright-field IHC were performed using SPSS 20.0 software (SPSS
Inc.). To evaluate survival probabilities in patients with low group sizes, two groups (low vs. high protein expression levels) were selected for each marker based on an even distribution of patients’ scores in
these groups. IHC results were then correlated with clinical data using univariable and multivariable Cox
insight.jci.org   https://doi.org/10.1172/jci.insight.93652
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Table 1. Cohort age, stage, grade, and follow-up data
No.
Median
Minimum
Maximum

Age(yr)

Follow-up (mo)

Stage

Grade

119
58
22
83

119
26
3
60

119
3
1
4

119
2
1
3

regression analysis. In multivariable Cox regression, T- and N-stage and grading were included as confounding factors. Survival probability was visualized using Kaplan-Meier graphs. A P value of less than
0.05 was considered as significant result. For Figure 1, 2-tailed unpaired t tests were performed using
PRISM, and a P value of less than 0.05 was considered significant.
For multiplex IHC, medians for all presented immune markers are summarized in Table 3. For multiplex
data, Kaplan-Meier survival curves were established using SPSS statistical software v23. For Figures 3, 6–12,
and 14, a median cutoff was used, log-rank and Breslow tests were performed, and a P value from the most
appropriate test was reported. A P value of less than 0.05 was considered significant. For SI studies, a binary
value for each category was assigned based on a median cutoff, the sum of all values was used to generate the
SI score. Analyses were appropriately corrected for multiple comparisons when comparing two or more groups.
Multivariate Cox regression incorporating stage and grade was performed where applicable. A P value of less
than 0.05 was considered significant. For Figure 4, linear regression was performed using PRISM, and 95% confidence interval is shown. R2 value is shown, and a P value of less than 0.05 was considered significant.
Study approval. The study was carried out in compliance with the Helsinki Declaration. The study was
approved by the ethics committee of the Medical Faculty of Martin Luther University Halle-Wittenberg
and the institutional review board of the Providence Portland Medical Center (12-075A).
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Table 2. Cohort sex, treatment, and survival percentages
Male (%)

62.0

Received radiation (%)
Received chemotherapy (%)
HPV– cases (%)
Survival at last follow-up (%)

40.0
100.0
51.8
75.9
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Table 3. Medians for all presented immune markers
CD4
CD8
FoxP3
Total PD-L1

Tumor

Stroma

43 cells/mm2
116 cells/mm2
74 cells/mm2
867 cells/mm2

784 cells/mm2
1127 cells/mm2
437 cells/mm2
432 cells/mm2
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